Telix Pharmaceuticals reports half-year revenue up 22% to US$477 million as adjusted EBITDA jumps 146%
AI Market Summary
Telix Pharmaceuticals reported strong half-year results: revenue +22% to US$477m, gross margin up to 55% (Precision Medicine 65%), and adjusted EBITDA +146% to US$52m. Profit included a US$40m Regeneron payment, while operating cash flow turned positive and cash reached US$252m. A Regeneron collaboration and refinancing via a US$600m 2031 convertible strengthen funding for late-stage R&D and global manufacturing expansion.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+3.29%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Telix Pharmaceuticals reported half-year revenue up 22% year on year to US$477 million, tracking to the upper end of its FY26 guidance. Adjusted EBITDA surged 146% to US$52 million, while gross margin improved to 55% and the Precision Medicine segment margin reached 65%. Profit after tax was US$38 million, including a US$40 million payment from Regeneron, and operating cash flow was positive at US$23 million. The company ended the period with a cash balance of US$252 million.
